Download PDF
Thromb Haemost 2005; 93(04): 794-795
DOI: 10.1055/s-0037-1616783
Letter to the Editor
Schattauer GmbH

Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers

Markus Hinder
1   sanofi-aventis, Science and Medical Affairs, Frankfurt, Germany,
,
Anne Paccaly
2   sanofi-aventis, Science and Medical Affairs, Bridgewater, New Jersey, USA
,
Annke Frick
1   sanofi-aventis, Science and Medical Affairs, Frankfurt, Germany,
,
Umesh Shukla
2   sanofi-aventis, Science and Medical Affairs, Bridgewater, New Jersey, USA
,
Kelly Simcox
2   sanofi-aventis, Science and Medical Affairs, Bridgewater, New Jersey, USA
,
Barry Miller
2   sanofi-aventis, Science and Medical Affairs, Bridgewater, New Jersey, USA
,
Alexander Gebauer
1   sanofi-aventis, Science and Medical Affairs, Frankfurt, Germany,
› Author Affiliations
Further Information

Publication History

Received 16 September 2004

Accepted after resubmission 25 January 2005

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Braunwald E, Antman EM, Beasley JW. et al. ACC/ AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40: 1366-74.
    CrossrefPubMedGoogle Scholar
  • 2 Bertrand ME, Simoons ML, Fox KAA. et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
    CrossrefPubMedGoogle Scholar
  • 3 Cohen M, Demers C, Gurfinkel EP. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
    CrossrefPubMedGoogle Scholar
  • 4 Antman EM, McCabe CH, Gurfinkel EP. et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
    CrossrefPubMedGoogle Scholar
  • 5 Chu V, Brown K, Colussi D. et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res 2001; 103: 309-24.
    CrossrefPubMedGoogle Scholar
  • 6 Rebello SS, Bentley RG, Morgan SR. et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol 2001; 133: 1190-8.
    CrossrefPubMedGoogle Scholar
  • 7 Paccaly AJ, Ozoux M, Frick A. et al. Pharmacokinetic/ pharmacodynamic relationships for factor-Xa inhibitor XRP0673 in early drug development. AAPS PharmSci 2002; 4 (Abstract W5241).
    PubMedGoogle Scholar
  • 8 Dyke CK, Becker RC. et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2382-8.
    PubMedGoogle Scholar
  • 9 Alexander JH, Dyke CK, Yang H. et al. The XaNADU- PCI PILOT Investigators. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004; 2: 234-41.
    CrossrefPubMedGoogle Scholar
  • 10 Umemura K, Kondo K, Ikeda Y, et al. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997; 78: 1381-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Cohen M, Théroux P, Weber S. et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273-81.
    CrossrefPubMedGoogle Scholar